Association between polymorphisms of LEP, LEPR, DRD2, HTR2A and HTR2C genes and risperidone- or clozapine-induced hyperglycemia

References

• Zhang J, Gallego J, Robinson D, et al. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16:1205–1218. doi:10.1017/S146114571200127723199972
   PubMed Web of Science ®Google Scholar
• Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001;158:518–526. doi:10.1176/appi.ajp.158.4.51811282684
   PubMed Web of Science ®Google Scholar
• Daumit GL, Goff DC, Meyer JM, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res. 2008;105:175–187. doi:10.1016/j.schres.2008.07.00618775645
   PubMed Web of Science ®Google Scholar
• Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008;13:27–35. doi:10.1038/sj.mp.400206617848919
   PubMed Web of Science ®Google Scholar
• Tschoner A, Engl J, Laimer M, et al. Metabolic side effects of antipsychotic medication. Int J Clin Pract. 2007;61:1356–1370. doi:10.1111/j.1742-1241.2007.01416.x17627711
   PubMed Web of Science ®Google Scholar
• Enez Darcin A, Yalcin Cavus S, Dilbaz N, et al. Metabolic syndrome in drug-naïve and drug-free patients with schizophrenia and in their siblings. Schizophr Res. 2015;166:201–206. doi:10.1016/j.schres.2015.05.00426004686
   PubMed Web of Science ®Google Scholar
• Pillinger T, Beck K, Gobjila C, et al. Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry. 2017;74:261–269. doi:10.1001/jamapsychiatry.2016.380328097367
   PubMed Web of Science ®Google Scholar
• Voruganti LP, Punthakee Z, Van Lieshout RJ, et al. Dysglycemia in a community sample of people treated for schizophrenia: the Diabetes in Schizophrenia in Central-South Ontario (DiSCO) study. Schizophr Res. 2007;96:215–222. doi:10.1016/j.schres.2007.07.01617764906
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–962. doi:10.1016/S0140-6736(13)60733-323810019
   PubMed Web of Science ®Google Scholar
• Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology. 2010;35:1997–2004. doi:10.1038/npp.2010.7820520598
   PubMed Web of Science ®Google Scholar
• Vancampfort D, Correll CU, Galling B, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry. 2016;15:166–174. doi:10.1002/wps.2030927265707
   PubMed Web of Science ®Google Scholar
• Mitchell AJ, Vancampfort D, Sweers K, et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and meta-analysis. Schizophr Bull. 2013;39:306–318. doi:10.1093/schbul/sbr14822207632
   PubMed Web of Science ®Google Scholar
• Hirsch L, Yang J, Bresee L, et al. Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf. 2017;40:771–781. doi:10.1007/s40264-017-0543-028585153
   PubMed Web of Science ®Google Scholar
• Newcomer J. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2015;19(Suppl. 1):1–93.
   Google Scholar
• Das-Munshi J, Ashworth M, Dewey ME, et al. Type 2 diabetes mellitus in people with severe mental illness: inequalities by ethnicity and age. Cross-sectional analysis of 588 408 records from the UK. Diabet Med. 2017;34:916–924. doi:10.1111/dme.1329827973692
   PubMed Web of Science ®Google Scholar
• Ward M, Druss B. The epidemiology of diabetes in psychotic disorders. Lancet Psychiatry. 2015;2:431–451. doi:10.1016/S2215-0366(15)00007-326360287
   PubMed Web of Science ®Google Scholar
• Whicher CA, Price HC, Holt RIG. Mechanisms in endocrinology: antipsychotic medication and type 2 diabetes and impaired glucose regulation. Eur J Endocrinol. 2018;78:R245–R258. doi:10.1530/EJE-18-0022
   Web of Science ®Google Scholar
• Scigliano G, Ronchetti G. Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis. CNS Drugs. 2013;27:249–257. doi:10.1007/s40263-013-0054-123533011
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment–pharmacological mechanisms. Pharmacol Ther. 2010;125:169–179. doi:10.1016/j.pharmthera.2009.10.01019931306
   PubMed Web of Science ®Google Scholar
• Gregoor JG, van der Weide J, Mulder H, et al. Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication. J Clin Psychopharmacol. 2009;29:21–25. doi:10.1097/JCP.0b013e31819359be19142102
   PubMed Web of Science ®Google Scholar
• Zhang XY, Tan YL, Zhou DF, et al. Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population. J Clin Psychopharmacol. 2007;27:246–251. doi:10.1097/jcp.0b013e318058241217502770
   PubMed Web of Science ®Google Scholar
• Templeman LA, Reynolds GP, Arranz B, et al. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics. 2005;15:195–200.15864111
   PubMedGoogle Scholar
• Reynolds GP, Zhang Z, Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry. 2003;160:677–679. doi:10.1176/appi.ajp.160.4.67712668355
   PubMed Web of Science ®Google Scholar
• Kang SH, Lee JI, Han HR, et al. Polymorphisms of the leptin and HTR2C genes and clozapine-induced weight change and baseline BMI in patients with chronic schizophrenia. Psychiatr Genet. 2014;24:249–256. doi:10.1097/YPG.000000000000005325304226
   PubMed Web of Science ®Google Scholar
• Madaan V, Bestha DP, Kolli V, et al. Clinical utility of the risperidone formulations in the management of schizophrenia. Neuropsychiatr Dis Treat. 2011;7:611–620. doi:10.2147/NDT.S1438522090797
   PubMed Web of Science ®Google Scholar
• Samara MT, Dold M, Gianatsi M, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry. 2016;73:199–210. doi:10.1001/jamapsychiatry.2015.295526842482
   PubMed Web of Science ®Google Scholar
• Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009;120:1640–1645. doi:10.1161/CIRCULATIONAHA.109.19264419805654
   PubMed Web of Science ®Google Scholar
• Lee AK, Bishop JR. Pharmacogenetics of leptin in antipsychotic associated weight gain and obesity-related complications. Pharmacogenomics. 2011;12:999–1016. doi:10.2217/pgs.11.4521787190
   PubMed Web of Science ®Google Scholar
• Kuo PH, Kao CF, Chen PY, et al. Polymorphisms of INSIG2, MC4R, and LEP are associated with obesity- and metabolic-related traits in schizophrenic patients. J Clin Psychopharmacol. 2011;31:705–711. doi:10.1097/JCP.0b013e318234ee8422020349
   PubMed Web of Science ®Google Scholar
• Barnard ND, Noble EP, Ritchie T, et al. D2 dopamine receptor Taq1A polymorphism, body weight, and dietary intake in type 2 diabetes. Nutrition. 2009;25(1):58–65. doi:10.1016/j.nut.2008.07.01218834717
   PubMed Web of Science ®Google Scholar
• Lane HY, Liu YC, Huang CL, et al. Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol. 2006;26:128–134. doi:10.1097/01.jcp.0000203196.65710.2b16633140
   PubMed Web of Science ®Google Scholar
• Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28:519–526. doi:10.1038/sj.npp.130002712629531
   PubMed Web of Science ®Google Scholar
• Leucht S, Samara M, Heres S, et al. Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophr Bull. 2015;41:1397–1402. doi:10.1093/schbul/sbv03725841041
   PubMed Web of Science ®Google Scholar
• Montastruc F, Palmaro A, Bagheri H, et al. Role of serotonin 5-HT2C and histamine H1receptors in antipsychotic-induced diabetes: a pharmacoepidemiological-pharmacodynamic study in VigiBase. Eur Neuropsychopharmacol. 2005;25:1556–1565. doi:10.1016/j.euroneuro.2015.07.010
   Web of Science ®Google Scholar
• Boumaiza I, Omezzine A, Rejeb J, et al. Relationship between leptin G2548A and leptin receptor Q223R gene polymorphisms and obesity and metabolic syndrome risk in Tunisian volunteers. Genet Test Mol Biomarkers. 2012;16:726–733. doi:10.1089/gtmb.2011.032422734460
   PubMed Web of Science ®Google Scholar
• Hong CJ, Liou YJ, Bai YM, et al. Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenet Genomics. 2010;20:359–366. doi:10.1097/FPC.0b013e3283397d0620375926
   PubMed Web of Science ®Google Scholar
• Gunes A, Melkersson KI, Scordo MG, et al. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J Clin Psychopharmacol. 2009;29:65–68. doi:10.1097/JCP.0b013e31819302c319142110
   PubMed Web of Science ®Google Scholar
• Hill MJ, Reynolds GP. Functional consequences of two HTR2C polymorphisms associated withantipsychotic-induced weight gain. Pharmacogenomics. 2011;5:727–734. doi:10.2217/pgs.11.16
   Web of Science ®Google Scholar
• Morton GJ, Gelling RW, Niswender KD, Morrison CD, Rhodes CJ, Schwartz MW. Leptin regulates insulin sensitivity via phosphatidylinositol-3-OH kinase signaling in mediobasal hypothalamic neurons. Cell Metab. 2005;2:411–420. doi:10.1016/j.cmet.2005.10.00916330326
   PubMed Web of Science ®Google Scholar
• Srisawasdi P, Vanwong N, Hongkaew Y, et al. Impact of risperidone on leptin and insulin in children and adolescents with autistic spectrum disorders. Clin Biochem. 2017;50:678–685. doi:10.1016/j.clinbiochem.2017.02.00328167244
   PubMed Web of Science ®Google Scholar
• Sukasem C, Vanwong N, Srisawasdi P, et al. Pharmacogenetics of risperidone induced insulin resistance in children and adolescents with autism spectrum disorder. Basic Clin Pharmacol Toxicol. 2018;12:42–50. doi:10.1111/bcpt.12970
   Web of Science ®Google Scholar
• Cheng L, Yu Y, Szabo A, et al. Palmitic acid induces central leptin resistance and impairs hepatic glucose and lipid metabolism in male mice. J Nutr Biochem. 2015;26:541–548. doi:10.1016/j.jnutbio.2014.12.01125724108
   PubMed Web of Science ®Google Scholar
• Cheng L, Yu Y, Zhang Q, et al. Arachidonic acid impairs hypothalamic leptin signaling and hepatic energy homeostasis in mice. Mol Cell Endocrinol. 2015;412:12–18. doi:10.1016/j.mce.2015.04.02525986657
   PubMed Web of Science ®Google Scholar
• Xuan J, Pan G, Qiu Y, et al. Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011;10:5433–5443. doi:10.1021/pr200679622007635
   PubMed Web of Science ®Google Scholar
• Piao L, Park J, Li Y, et al. SOCS3 and SOCS6 are required for the risperidone-mediated inhibition of insulin and leptin signaling in neuroblastoma cells. Int J Mol Med. 2014;33:1364–1370. doi:10.3892/ijmm.2014.169324626642
   PubMed Web of Science ®Google Scholar
• Le Stunff C, Le Bihan C, Schork NJ, et al. A common promoter variant of the leptin gene is associated with changes in the relationship between serum leptin and fat mass in obese girls. Diabetes. 2000;49:2196–2200. doi:10.2337/diabetes.49.12.219611118025
   PubMed Web of Science ®Google Scholar
• Shen J, Ge W, Zhang J, et al. Leptin −2548G/A gene polymorphism in association with antipsychotic-induced weight gain: a meta-analysis study. Psychiatr Danub. 2014;26:145–151.24909251
   PubMed Web of Science ®Google Scholar
• Brandl EJ, Frydrychowicz C, Tiwari AK, et al. Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic induced body weight gain. Prog. Neuropsychopharmacol. Biol Psychiatry. 2012;38:134–141.
   Web of Science ®Google Scholar
• Morris DL, Rui L. Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab. 2009;297:E1247–E1259. doi:10.1152/ajpendo.00274.200919724019
   PubMed Web of Science ®Google Scholar
• Moon HS, Dalamaga M, Kim SY, et al. Leptin’s role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev. 2013;34:377–412. doi:10.1210/er.2012-105323475416
   PubMed Web of Science ®Google Scholar
• Hoffstedt J, Eriksson P, Mottagui-Tabar S, et al. A polymorphism in the leptin promoter region (−2548 G/A) influences gene expression and adipose tissue secretion of leptin. Horm Metab Res. 2002;34:355–359. doi:10.1055/s-2002-3346612189581
   PubMed Web of Science ®Google Scholar
• Calapai G, Corica F, Corsonello A, et al. Leptin increases serotonin turnover by inhibition of brain nitric oxide synthesis. J Clin Invest. 1999;104:975–982. doi:10.1172/JCI586710510338
   PubMed Web of Science ®Google Scholar
• von Meyenburg C, Langhans W, Hrupka BJ. Evidence for a role of the 5-HT2C receptor in central lipopolysaccharide-, interleukin-1 beta-, and leptin-induced anorexia. Pharmacol Biochem Behav. 2003;74:1025–1031. doi:10.1016/S0091-3057(03)00030-312667918
   PubMed Web of Science ®Google Scholar
• Klemettilä JP, Kampman O, Seppälä N, et al. Association study of the HTR2C, leptin and adiponectin genes and serum marker analyses in clozapine treated long-term patients with schizophrenia. Psychiatry. 2015;30:296–302.
   Google Scholar
• Gregoor JG, Mulder H, Cohen D, et al. Combined HTR2C-LEP genotype as a determinant of obesity in patients using antipsychotic medication. J Clin Psychopharmacol. 2010;30:702–705. doi:10.1097/JCP.0b013e3181fa05a221105285
   PubMed Web of Science ®Google Scholar
• Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011;17:97–107. doi:10.1016/j.molmed.2010.10.01021185230
   PubMed Web of Science ®Google Scholar
• Zhou L, Sutton GM, Rochford JJ, et al. Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways. Cell Metab. 2007;6:398−405. doi:10.1016/j.cmet.2007.10.00817983585
   PubMed Web of Science ®Google Scholar
• Kang SH, Lee JI, Chang AK, et al. Genetic polymorphisms in the HTR2C and peroxisome proliferator-activated receptors are not associated with metabolic syndrome in patients with schizophrenia taking clozapine. Psychiatry Investig. 2011;8:262–268. doi:10.4306/pi.2011.8.3.262
   PubMed Web of Science ®Google Scholar
• Manu P, Correll CU, Van Winkel R, et al. Prediabetes in patients treated with antipsychotic drugs. J Clin Psychiatry. 2012;73:460–466. doi:10.4088/JCP.10m0682222225552
   PubMed Web of Science ®Google Scholar